1. Home
  2. MIRM vs TGL Comparison

MIRM vs TGL Comparison

Compare MIRM & TGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • TGL
  • Stock Information
  • Founded
  • MIRM 2018
  • TGL 2020
  • Country
  • MIRM United States
  • TGL United States
  • Employees
  • MIRM N/A
  • TGL N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • TGL Retail: Computer Software & Peripheral Equipment
  • Sector
  • MIRM Health Care
  • TGL Technology
  • Exchange
  • MIRM Nasdaq
  • TGL Nasdaq
  • Market Cap
  • MIRM 2.5B
  • TGL 4.1M
  • IPO Year
  • MIRM 2019
  • TGL 2022
  • Fundamental
  • Price
  • MIRM $52.66
  • TGL $1.14
  • Analyst Decision
  • MIRM Strong Buy
  • TGL
  • Analyst Count
  • MIRM 9
  • TGL 0
  • Target Price
  • MIRM $66.22
  • TGL N/A
  • AVG Volume (30 Days)
  • MIRM 456.2K
  • TGL 233.1K
  • Earning Date
  • MIRM 08-06-2025
  • TGL 08-25-2025
  • Dividend Yield
  • MIRM N/A
  • TGL N/A
  • EPS Growth
  • MIRM N/A
  • TGL N/A
  • EPS
  • MIRM N/A
  • TGL N/A
  • Revenue
  • MIRM $379,251,000.00
  • TGL $1,468,790.00
  • Revenue This Year
  • MIRM $35.83
  • TGL N/A
  • Revenue Next Year
  • MIRM $16.83
  • TGL N/A
  • P/E Ratio
  • MIRM N/A
  • TGL N/A
  • Revenue Growth
  • MIRM 69.31
  • TGL N/A
  • 52 Week Low
  • MIRM $36.17
  • TGL $1.01
  • 52 Week High
  • MIRM $54.23
  • TGL $129.00
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 64.66
  • TGL 37.27
  • Support Level
  • MIRM $49.22
  • TGL $1.22
  • Resistance Level
  • MIRM $53.86
  • TGL $1.35
  • Average True Range (ATR)
  • MIRM 1.57
  • TGL 0.09
  • MACD
  • MIRM 0.08
  • TGL 0.04
  • Stochastic Oscillator
  • MIRM 79.63
  • TGL 23.53

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TGL Treasure Global Inc.

Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.

Share on Social Networks: